Apogee Therapeutics (APGE) to Release Earnings on Monday

Apogee Therapeutics (NASDAQ:APGE) is projected to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.12) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 9:30 AM ET.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.02. On average, analysts expect Apogee Therapeutics to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Apogee Therapeutics Stock Up 3.8%

APGE traded up $3.06 during trading hours on Monday, reaching $83.81. 219,325 shares of the company’s stock traded hands, compared to its average volume of 971,806. The firm has a 50-day moving average price of $78.89 and a 200 day moving average price of $72.41. Apogee Therapeutics has a 52-week low of $34.34 and a 52-week high of $95.32. The firm has a market capitalization of $5.18 billion, a PE ratio of -19.89 and a beta of 0.69.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on APGE. Stifel Nicolaus set a $133.00 price objective on Apogee Therapeutics in a report on Tuesday, January 6th. BTIG Research reiterated a “buy” rating and issued a $137.00 target price on shares of Apogee Therapeutics in a report on Monday, March 23rd. Wolfe Research initiated coverage on Apogee Therapeutics in a report on Wednesday, January 7th. They issued a “peer perform” rating for the company. Rothschild & Co Redburn initiated coverage on Apogee Therapeutics in a report on Friday. They issued a “buy” rating and a $140.00 target price for the company. Finally, Truist Financial initiated coverage on Apogee Therapeutics in a report on Tuesday, March 17th. They issued a “hold” rating and a $83.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Apogee Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $112.73.

Insider Activity

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $63.35, for a total transaction of $1,267,000.00. Following the transaction, the chief executive officer directly owned 1,172,987 shares of the company’s stock, valued at $74,308,726.45. This represents a 1.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Carl Dambkowski sold 5,500 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $84.84, for a total value of $466,620.00. Following the transaction, the insider directly owned 208,398 shares in the company, valued at $17,680,486.32. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 76,500 shares of company stock worth $5,633,495 over the last ninety days. 24.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Apogee Therapeutics

Large investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC acquired a new position in shares of Apogee Therapeutics in the 4th quarter valued at $37,000. Quantbot Technologies LP acquired a new stake in Apogee Therapeutics during the 3rd quarter worth about $96,000. BNP Paribas Financial Markets lifted its position in Apogee Therapeutics by 34.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock worth $158,000 after acquiring an additional 941 shares during the period. Ensign Peak Advisors Inc acquired a new stake in Apogee Therapeutics during the 4th quarter worth about $170,000. Finally, Quarry LP acquired a new stake in Apogee Therapeutics during the 4th quarter worth about $189,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.